News from kiadis pharma A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 30, 2014, 03:00 ET

Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation by EMA for the Treatment of Acute Myeloid Leukemia

Kiadis Pharma B.V. ("Kiadis Pharma" or "the Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments...

Sep 03, 2014, 02:00 ET

Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer

   ~ Clinical and Business Development expert re-joins the Company ~  Kiadis Pharma B.V. ("Kiadis Pharma", "Kiadis" or "the...

Mar 24, 2014, 03:00 ET

Kiadis Pharma Organizes a Satellite Symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that...

Jan 29, 2014, 02:00 ET

Kiadis Pharma Initiates Collaboration for Personalized Immunotherapies Using ATIR[TM]with Technische Universität München within Munich Biotech Cluster

~ Prof. Dr. Angela Krackhardt from the Klinikum rechts der Isar of the Technische Universität München to lead the...

Dec 05, 2013, 02:00 ET

Kiadis Pharma Participates in Haploidentical Transplantation 2013 Forum

~ Prior to the American Society of Hematology Annual Meeting ~ Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing...

Nov 18, 2013, 02:00 ET

Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR™

~ 6 month follow-up data expected in H1 2014  ~  Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing...

Oct 07, 2013, 02:00 ET

Kiadis Pharma Secures Manufacturing Services Agreement for its Phase II Clinical Program with Blood Cancer Treatment ATIR™ with the German Red Cross Blood Donor Service

~ Technology transfer successfully completed and manufacturing underway ~ Kiadis Pharma B.V., a clinical stage biopharmaceutical company...

Sep 11, 2013, 02:00 ET

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™ and Study Meets Primary Objective

~ 67% survival demonstrated after 5 years and no transplant related mortalities ~ Manfred Ruediger, CEO of Kiadis Pharma, gives more...

Jul 23, 2013, 02:00 ET

Kiadis Pharma to Receive GMP Manufacturing License and GMP Certificate

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that its Quality Control...

Jun 26, 2013, 02:00 ET

Kiadis Pharma Awarded a €3 Million Innovation Credit from the Dutch Government for Phase II Clinical Development Program

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it will receive an...

Jan 04, 2011, 12:14 ET

Kiadis Pharma signe un accord de licence avec Hospira pour la commercialisation de l'ATIR(TM) en Europe et en Asie

- Ce partenariat devrait permettre de faire progresser ce produit innovant de transplantation de cellules souches Kiadis Pharma, une...

Jan 04, 2011, 11:01 ET

Kiadis Pharma unterzeichnet Lizenzvertrag mit Hospira, um ATIR(TM) in Europa und Asien zu vermarkten

- Die Partnerschaft soll das innovative Produkt zur Stammzellentransplantation fördern Kiadis Pharma, ein biopharmazeutisches...

Jan 04, 2011, 07:49 ET

Kiadis Pharma firma un acuerdo de licencia con Hospira para comercializar ATIR(TM) en Europa y Asia

- La asociación conseguirá el avance del innovador producto de transplante de células madre Kiadis Pharma, una...

Jan 04, 2011, 04:23 ET

Kiadis Pharma sluit een licentieovereenkomst met Hospira voor commercialisatie van ATIR(TM) in Europa en Azië

- Partnership stimuleert ontwikkeling van innovatief stamceltransplantatieproduct Kiadis Pharma, een Nederlands biofarmaceutisch...

Jul 08, 2010, 06:00 ET

Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States

Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the...

Apr 28, 2010, 06:00 ET

Kiadis Pharma Provides ATIR(TM) Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality

Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants. ATIR™...

Nov 30, 2009, 08:00 ET

Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial...

Apr 08, 2009, 08:53 ET

Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations

Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow...

Jan 06, 2009, 04:59 ET

Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer

Biopharmaceutical Company Kiadis Pharma focused on the development of innovative cell based therapeutics in the field of bone marrow...

Dec 08, 2008, 08:51 ET

Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA

Biopharmaceutical company Kiadis Pharma announces today that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc(TM) Orphan...